Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 74.07 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $40.80 million which beat the analyst consensus estimate of $40.10 million by 1.75 percent. This is a 10.41 percent decrease over sales of $45.54 million the same period last year.